MARKET

QNRX

QNRX

Quoin Pharmaceuticals Ltd
NASDAQ
0.9500
+0.0800
+9.20%
Opening 15:50 03/28 EDT
OPEN
0.8800
PREV CLOSE
0.8700
HIGH
0.9700
LOW
0.8601
VOLUME
158.44K
TURNOVER
0
52 WEEK HIGH
12.00
52 WEEK LOW
0.8000
MARKET CAP
3.50M
P/E (TTM)
-0.0985
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at QNRX last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at QNRX last week (0311-0315)?
Weekly Report · 03/18 12:21
Maxim Group Maintains Buy Rating for Quoin Pharmaceuticals: Here's What You Need To Know
Maxim Group has maintained its Buy rating of Quoin Pharmaceuticals and lower its price target from $15.00 to $4.00. The company is a pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Shares of quoin pharmaceuticals are trading up 2.0% over the last 24 hours.
Benzinga · 03/15 17:00
Quoin Pharmaceuticals Price Target Cut to $4.00/Share From $15.00 by Maxim Group
Dow Jones · 03/15 15:25
Quoin Pharmaceuticals Is Maintained at Buy by Maxim Group
Dow Jones · 03/15 15:25
Maxim Group Maintains Buy on Quoin Pharmaceuticals, Lowers Price Target to $4
Benzinga · 03/15 15:15
Quoin Pharmaceuticals GAAP EPS of -$2.08
Seeking Alpha · 03/13 20:21
Quoin Pharmaceuticals: Q4 Earnings Insights
Quoin Pharmaceuticals reported its Q4 earnings on March 13. The company beat estimates by 10.0%. The company's revenue was down $0 from the same period last year. Last quarter the company beat on EPS by $0.77 and the share price fell 8.0% the next day.
Benzinga · 03/13 20:15
More
About QNRX
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.

Webull offers Quoin Pharmaceuticals Ltd - ADR stock information, including NASDAQ: QNRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QNRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading QNRX stock methods without spending real money on the virtual paper trading platform.